Ftse Mib
33.541,98
-0,49%
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
NASDAQ
17.805,16
0,49%
Bitcoin
60.887,30
0,12%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Prevail Therapeutics Inc (PRVL) Prevail Therapeutics Inc (PRVL) Notizie

PRVL

Prevail Therapeutics (PRVL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRVL
DataOraFonteTitoloSimboloCompagnia
16/02/202122:43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PRVLPrevail Therapeutics Inc
01/02/202112:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:PRVLPrevail Therapeutics Inc
29/01/202122:16Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PRVLPrevail Therapeutics Inc
29/01/202112:13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRVLPrevail Therapeutics Inc
27/01/202112:12Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PRVLPrevail Therapeutics Inc
26/01/202123:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202122:39Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202115:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202115:03Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202114:55PR Newswire (US)Lilly Completes Acquisition of Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc
20/01/202113:01Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:PRVLPrevail Therapeutics Inc
20/01/202112:44Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202014:50Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202014:34Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202013:08Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202023:05Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202013:35Dow Jones NewsLilly Raises 2020 Guidance, Sets 2021 OutlookNASDAQ:PRVLPrevail Therapeutics Inc
15/12/202013:17Dow Jones NewsLilly to Buy Prevail Therapeutics for Up to $1.04 BillionNASDAQ:PRVLPrevail Therapeutics Inc
15/12/202012:39Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202012:15PR Newswire (US)Lilly Announces Agreement to Acquire Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc
11/12/202013:00GlobeNewswire Inc.Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of...NASDAQ:PRVLPrevail Therapeutics Inc
30/11/202013:00GlobeNewswire Inc.Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal DementiaNASDAQ:PRVLPrevail Therapeutics Inc
19/11/202001:01GlobeNewswire Inc.Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001NASDAQ:PRVLPrevail Therapeutics Inc
13/11/202013:21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRVLPrevail Therapeutics Inc
13/11/202013:00GlobeNewswire Inc.Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsNASDAQ:PRVLPrevail Therapeutics Inc
10/11/202013:00GlobeNewswire Inc.Prevail Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:PRVLPrevail Therapeutics Inc
02/11/202013:00GlobeNewswire Inc.Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEONASDAQ:PRVLPrevail Therapeutics Inc
27/10/202012:00GlobeNewswire Inc.Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher DiseaseNASDAQ:PRVLPrevail Therapeutics Inc
18/09/202021:04GlobeNewswire Inc.Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitNASDAQ:PRVLPrevail Therapeutics Inc
11/09/202014:29Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PRVLPrevail Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRVL

La tua Cronologia

USOTC
IMTS
Interactive Motorsports ... (GM)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network